Cytel Inc.

Shaping the future of drug development with software solutions, innovative consulting and proven clinical research services.

[Cytel Inc. @cytel]

JCAs are changing how indirect comparative evidence must be generated and defended, and direct head-to-head data may not always be available or sufficiently aligned. MAICs can help address some of these evidence gaps — we discuss what makes them credible.  https://t.co/r0nmHjVKUr

[Cytel Inc. @cytel]

In just one week, Cytel will be at the 2026 Bay Area Biotech-Pharma Statistics Workshop in Foster City!

Book a meeting with a member of our team at BBSW here: https://t.co/ZIlNjq505l

See you in Foster City! 👋

[Cytel Inc. @cytel]

While RCTs remain the cornerstone of regulatory and HTA decision-making, advances in computational science are creating entirely new forms of evidence. Dalia Dawoud discuses two of the most promising developments: in-silico data & MIDD. Learn more:
https://t.co/4cOFOX1vyQ

[Cytel Inc. @cytel]

Cytel will be at PHUSE EU Connect 2026 in Glasgow!

📍 Stop by Booth 8 to speak with the Cytel team.

See our upcoming presentations and book a meeting with a member of our team at PHUSE EU here: https://t.co/1YKrYmu4Ms

See you in Glasgow! 👋

[Cytel Inc. @cytel]

Independent physician review is the cornerstone of endpoint adjudication, but much of an Endpoint Adjudication Committee's efficiency and effectiveness is determined long before before a physician ever opens a case. Learn more: https://t.co/d7yNT4OgJV

[Cytel Inc. @cytel]

NICE has published its AI Delivery Plan. Dalia Dawoud and Manuel Cossio discuss what HTA, HEOR, and market access professionals need to know and how sponsors can prepare as NICE's vision moves from experimentation to implementation.

https://t.co/SRUeYoylkq

[Cytel Inc. @cytel]

Join us at our SCOPE Europe Drinks Reception in Barcelona tomorrow evening!

Meet the Cytel team and continue the conversations that matter most. Space is limited — please register early to secure your place.

https://t.co/N60Iu0I2Ks

We hope to see you there!

[Cytel Inc. @cytel]

Independent physician review is the cornerstone of endpoint adjudication, but much of an Endpoint Adjudication Committee's efficiency and effectiveness is determined long before before a physician ever opens a case. Learn more: https://t.co/IYVyhChowZ

[Cytel Inc. @cytel]

Cytel will be at SCOPE Europe! Our team is ready to help you bring greater visibility and predictability to your next clinical trial through connected trial design and clinical data oversight.

Book your meeting today: https://t.co/H89aWeJQ0b

We hope to see you there!

[Cytel Inc. @cytel]

How do you build an FSP workforce that controls costs without compromising quality, capability, or delivery? Join our experts for a webinar that explores how smarter workforce models can strengthen delivery, optimize resources, and create lasting value: https://t.co/Ph76WPpdbi

[Cytel Inc. @cytel]

Next week, the Cytel team will be in Denver at the 2026 CDISC US Interchange!

Stop by and say hello to our team at Booth 6.

See you in Denver! https://t.co/4NDJg7TZ0m

[Cytel Inc. @cytel]

How do you build an FSP workforce that controls costs without compromising quality, capability, or delivery? Join our experts for a webinar that explores how smarter workforce models can strengthen delivery, optimize resources, and create lasting value: https://t.co/ZKWPtDaCXP

[Cytel Inc. @cytel]

Cytel will be at SCOPE Europe! Our team is ready to help you bring greater visibility and predictability to your next clinical trial through connected trial design and clinical data oversight.

Book your meeting today: https://t.co/P1xlvk9sWh

We hope to see you there!

[Cytel Inc. @cytel]

Workforce planning is often approached through the immediate needs of a role. But this can overlook something more fundamental. We discuss the broader questions sponsors should be asking to build teams that can continue to deliver well into the future.
https://t.co/Q4UfzQljKP

[Cytel Inc. @cytel]

Parkinson’s disease is the second-most common neurodegenerative disease affecting over 11 million people globally. We discuss common endpoints used in clinical trials with an illustrative case study on how those endpoints may be analyzed.
https://t.co/feTaibq4sw

[Cytel Inc. @cytel]

NICE has published its AI Delivery Plan. Dalia Dawoud and Manuel Cossio discuss what HTA, HEOR, and market access professionals need to know and how sponsors can prepare as NICE's vision moves from experimentation to implementation.

https://t.co/FywIN4LlsR

[Cytel Inc. @cytel]

In the fight against rare diseases, data is our most precious resource — and greatest challenge. We discuss how, through a case study on IOPD, propensity score methods can be used to estimate treatment effectiveness in this rare disease setting. https://t.co/3RCBVgaRaZ

[Cytel Inc. @cytel]

How do you build an FSP workforce that controls costs without compromising quality, capability, or delivery? Join our experts for a webinar that explores how smarter workforce models can strengthen delivery, optimize resources, and create lasting value: https://t.co/nJBFhOGzs7

[Cytel Inc. @cytel]

On September 24, join Manuel Cossio and Nicolas Rouillé as they explore the applications delivering tangible impact across biometrics and R&D, from data management and document automation to statistical programming.

Register today! https://t.co/78XGwtIx2O

[Cytel Inc. @cytel]

For sponsors planning umbrella, basket, or platform trials, recent FDA guidance has shifted the conversation toward what is required to ensure they are sufficiently rigorous for regulatory decision-making. We share what sponsors need to consider: https://t.co/VNNl5eNm4T